Cancer is not one disease – that’s why the efforts to unravel a cure have been so challenging. Each type of cancer is different, and tumors vary genetically not just from type to type but from patient to patient. To better understand the molecular thumbprint that drive individual cancers, scientists have turned to next-generation sequencing (NGS). This new technology sequences DNA of tumors. The problem - genomic sequencing generates a lot of data. The American Association for Cancer Research (AACR) thinks it has a solution - the pilot project is dubbed GENIE, short for Genomics, Evidence, Neoplasia, Information, Exchange, and is the result of 18 months of discussions with cancer centers that are amassing genomic data at a faster rate than they know what to do with. The amazing part? GENIE can assist physicians in their effort to predict a patient response to certain drugs, based on the molecular profile of their own tumor and so much more.